X

Bal Pharma Ltd Stock Analysis

Small Cap
Evaluated by 458 users | BSE: 524824 | NSE: BALPHARMA |
Pharmaceuticals & Drugs
Bal Pharma, incorporated in 1987 is engaged in the business interest in area of manufacturing API, finished formulations, ayurvedic and research and development. It is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 5.33%8.9%9.79%9.73%7.87%5.75%6.92%7.64%8.95%-0.26%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 114140148179187198226208223171
Y-o-Y Gr. Rt.-22.1%5.9%20.9%4.6%5.6%14.3%-8.1%7.4%-23.5%
Adjusted EPS (Rs.) 0.163.173.754.262.81.652.343.544.59-6.59
Y-o-Y Gr. Rt.-1881.3%18.3%13.6%-34.3%-41.1%41.8%51.3%29.7%-243.6%
Book Value per Share (Rs.) 34.6437.8841.0643.4841.6342.4846.9850.9754.2346.53
Adjusted Net Profit 0.23.444.73.62.13.356.5-9.3
Net Op. Cash Flow (Rs. Cr.) 11.312.916.113.314.41.36.412.611.621.6
Debt to Cash Flow from Ops 5.114.423.33.923.4454.5511.657.29.054.61
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Bal Pharma Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 4.5%-1.8%-8.9%-23.5%
Adjusted EPS -251.2%-218.7%-241.2%-243.6%
Book Value per Share 3.32.3-0.3-14.2
Share Price 12.6% -17.5% -17.2% 39.4%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 0.468.759.37106.823.785.387.228.73-13.07
Operating Profit Margin (%) 9.4210.8111.649.999.378.678.911.039.184.16
Net Profit Margin (%) 0.142.42.682.651.921.071.472.422.92-5.47
Debt to Equity 1.591.431.231.080.921.281.111.251.361.51
Working Capital Days 231211215189193211221290303386
Cash Conversion Cycle 1131039576727178112129179
Entity Percentage Holding
Promoters 42.45%
Institutions 0.01%
Non-Institutions 57.53%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Bal Pharma Ltd's performance infers:

Bal Pharma Ltd earnings have declined by -218.7%, whereas share price has depreciated -17.5% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Bal Pharma Ltd share prices over the last 10 years. Here is what we found out:

Bal Pharma Ltd share price has depreciated 5.3% annually over the past ten years.

Bal Pharma, incorporated in 1987 is engaged in the business interest in area of manufacturing API, finished formulations, ayurvedic and research and development. It is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives.

The company exports APIs to countries like Japan, Australia,

Bal Pharma, incorporated in 1987 is engaged in the business interest in area of manufacturing API, finished formulations, ayurvedic and research and development. It is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives.

The company exports APIs to countries like Japan, Australia, Spain, UK, Canada, Nigeria, Iceland, Slovenia, Romania, Argentina, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, Turkey, Egypt, Korea, Venezuela, Italy, Portugal, Morocco, Poland, Netherlands, Syria, Bangladesh, and Indonesia, etc.

It offers products for treatment for diabetes, cardiometabolics, gynaecology, dermatology, gastroenterology, orthopaedics, ENT and multi-speciality segments.

In India, the company operates its marketing through 5 divisions namely Multi-Specialty, Glyduz, Servetus, Bal Vedics and Zennova. It has distribution network of 1000 wholesalers that caters over 1,00,000 retailers.

The company produces range of APIs that includes Anti Histamine, Platelet inhibitor, Antidiabetic, Anti Convulsant, urinary incontinence, Neuropathic pain, Anti allergy, Anti inflammatory, Diuretic, Acne Treatment etc

Bal Pharma's R&D unit is engaged in developing processes for novel bulk actives (active pharmaceutical ingredients, APIs) and new chemical substances for therapeutic applications.

The company’s manufacturing facilities has been approved by WHO-GMP and has obtained the ISO 9001:2000 accreditations for quality management.

Businesses

  • API / Intermediates
  • Finished Formulations
  • Ayurvedic
  • Research and Development

Future Plans

Bal Pharma is planning to set up new facility in Uttaranchal, with an objective to enter into regulated markets. The company also plans to foray in the business of contract manufacturing.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback